menu
    • menu

    Company profile for Point Biopharma

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in late 2019, POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible outcomes.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Point BiopharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    4850 West 78th St. Indianapolis, Indiana 46268
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.pointbiopharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/point-biopharma/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/PointBiopharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lilly signs $140M upfront partnership with Radionetics in radiopharma play
    Lilly signs $140M upfront partnership with Radionetics in radiopharma play

    01 Jul 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/lilly-signs-140m-upfront-partnership-radionectics-latest-radiopharma-play

    FIERCE BIOTECH
    01 Jul 2024
    Share Share
    Lilly Completes Acquisition of POINT Biopharma
    Lilly Completes Acquisition of POINT Biopharma

    27 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-point-biopharma-302022791.html

    PR NEWSWIRE
    27 Dec 2023
    Share Share
    POINT Biopharma shareholders get long-awaited radioligand therapy data
    POINT Biopharma shareholders get long-awaited radioligand therapy data

    20 Dec 2023

    // PRESS RELEASE

    https://www.pointbiopharma.com/press-releases/splash-topline-results

    PRESS RELEASE
    20 Dec 2023
    Share Share
    Lantheus and POINT Biopharma Announce Positive Results from SPLASH Trial
    Lantheus and POINT Biopharma Announce Positive Results from SPLASH Trial

    18 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/18/2797730/0/en/Lantheus-and-POINT-Biopharma-Announce-Positive-Topline-Results-from-Pivotal-SPLASH-Trial-in-Metastatic-Castration-Resistant-Prostate-Cancer.html

    GLOBENEWSWIRE
    18 Dec 2023
    Share Share
    Deadline for Point investors as data meets Lilly's expectations
    Deadline for Point investors as data meets Lilly's expectations

    18 Dec 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/point-breaks-open-phase-3-data-showing-how-drug-14b-lilly-buyout-saga-matches-pluvicto

    Nick Paul Taylor FIERCE BIOTECH
    18 Dec 2023
    Share Share
    Eli Lilly extends tender offer to buy Point Biopharma after low participation
    Eli Lilly extends tender offer to buy Point Biopharma after low participation

    17 Nov 2023

    // REUTERS

    https://www.reuters.com/markets/deals/lilly-extends-tender-offer-acquire-point-biopharma-dec-1-2023-11-17/

    REUTERS
    17 Nov 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search